ResMedMEX:RMD 99 Operating Margin % is 34.92% as of Mar. 2026, which is 28% above its 10-year median of 27.32. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, ResMed ranks better than 97.43% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. ResMed's Operating Income for the
three
months ended in Mar. 2026 was MXN9,013 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was MXN25,812 Mil. Therefore, ResMed's Operating Margin % for the quarter that ended in Mar. 2026 was 34.92%.
Good Sign:
ResMed Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for ResMed's Operating Margin % or its related term are showing as below:
MEX:RMD'
s Operating Margin % Range Over the Past 10 Years
Min: 22.1 Med: 27.32 Max: 34.6
Current: 34.6
MEX:RMD's Operating Margin % is ranked better than 97.43% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs MEX:RMD: 34.60
ResMed's 5-Year Average Operating Margin % Growth Rate was 2.90% per year.
ResMed's Operating Income for the
three
months ended in Mar. 2026 was MXN9,013 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was MXN35,051 Mil.
ResMed (MEX:RMD) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ResMed Operating Margin % Related Terms
ResMed Operating Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ResMed's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a Operating Margin % of 34.92% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ResMed and its competitors. This is 28% above median its historical median of 27.32. Over the past decade, ResMed's Operating Margin % has ranged from 22.10 to 34.60. According to the industry distribution chart, ResMed ranks #21 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 2.6%.
Is ResMed's Operating Margin % too high?
ResMed's current Operating Margin % of 34.92% is 28% above median its 10-year median of 27.32. Over the past 10 years, this metric has ranged from a low of 22.10 to a high of 34.60. The Medical Devices & Instruments industry median Operating Margin % is 3.47. ResMed's value of 34.92% is 907.8% above this industry median. Based on the distribution chart, ResMed ranks #21 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Operating Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #21 out of 816 companies for Operating Margin %. This places ResMed in the top 3% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.47. ResMed's value of 34.92% is 907.8% above this benchmark. Historically, ResMed's own Operating Margin % has ranged from 22.10 to 34.60 over the past decade. While the company's 10-year median is 27.32 vs. the industry median of 3.47, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Operating Margin % of 34.92% is 907.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Operating Margin % is 34.92%, which is 28% above median its own 10-year median of 27.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current Operating Margin % is 34.92%, which is 28% above median its 10-year median of 27.32 and 907.8% above the Medical Devices & Instruments industry median of 3.47. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Operating Margin % is 34.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for MEX:RMD:
Operating Margin %: 34.92% (28% above median its 10-year median of 27.32)
GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
Industry Position: 907.8% above the Medical Devices & Instruments median (#21 of 816)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
